Originally published by our sister publication Pharmacy Practice News
By Gina Shaw
More than three-fourths of respondents to the ASHP 12th annual Pharmacy Forecast, released at the ASHP 2023 Midyear Clinical Meeting & Exhibition, held in Anaheim, Calif., believe that formulary and policy decisions for ultra–high-cost therapies—such as rare and orphan drugs, gene therapy, and chimeric antigen receptor T-cell therapy—will be decided by payor or service-line stakeholders,